Enorama Pharma AB

As of June 30, 2026, Enorama Pharma AB carries a market capitalization of 20.14M, placing it among publicly traded companies globally. Its enterprise value stands at 18.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Enorama Pharma AB has 74.59M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 13.91, and the price-to-book ratio stands at -0.40.

These figures are as of June 30, 2026. The EV/Sales ratio of 12.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 18.04M versus a market cap of 20.14M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Enorama Pharma AB maintains a current ratio of 0.21, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -373.71, reflecting losses generated across the asset base. The company generates approximately 340,705.88 in revenue per employee across its workforce of 4.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.49 indicates how many times Enorama Pharma AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Enorama Pharma AB's stock has declined approximately 66.51% over the past 52 weeks. The 50-day moving average sits at 0.77, while the 200-day moving average is 0.69.

Over the twelve months ended June 30, 2026, Enorama Pharma AB generated 1.45M in revenue and converted that into -59.68M in net income, yielding earnings per share of -0.80. EBITDA reached -53.03M, while operating income came in at -53.39M.

These figures are as of June 30, 2026. Total book value stands at -50.44M, with working capital of -25.88M providing operational flexibility.

Enorama Pharma AB produced -53.87M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -53.87M - equivalent to -0.72 per share.

Over the twelve months ended June 30, 2026, Enorama Pharma AB posted a gross margin of -334.88, reflecting its pricing power and cost economics. The operating margin of -3,687.43 and net profit margin of -4,121.55 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -267.50: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -260.65, meaning Enorama Pharma AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Enorama Pharma AB's most recent stock split took place on March 6, 2024 with a 80:99 split ratio.